Product
Mebeverine+Simethicone
1 clinical trial
1 indication
Indication
Irritable Bowel SyndromeClinical trial
Multicenter, Randomized, Parallel-group, Open-label, Comparative Clinical Study to Evaluate Efficacy and Safety of Mebeverine+Simethicone Fixed-dose Combination Versus Duspatalin® (Mebeverine) and Versus Espumisan® (Simethicone) in Patients With Functional Bowel Disorders With Abdominal Pain and Excess Gas FormationStatus: Completed, Estimated PCD: 2021-05-18